PREMIUM
REGULAR CONTENT (New)
MEMBER . FORUM
Welcome to RXI!
Members
chen
View full Profile
View all Profiles
Edit your Profile
Login.
Email
Password
Remember Me
Join Now
Forgotten Password
Content & Disclosure
Charts & Data
Resources
Sitemap
PREMIUM
Options Strategy: Cypress Biosciences Revisited
Reiterating Options Strategy for Unloved Cancer Drug Maker
A Profitable Sell Recommendation
Ariad Pharma Going Forward
Going Forward
Lower We Go
FDA Panel Rules in Favor of Questcor’s Acthar Gel
Al & Tipper Have Seperated
A Game Plan for the Back Half of 2010
Long & Short Term Options Strategies for a Promising but Unloved Drug Maker
Specialty Drug Maker with Promising Treatment for Elderly
Specialty Drug Maker with Two Significant Catalysts in 2010
Promising Cancer Drug Maker Has Three Pending Catalysts in 2010
A Must Own Medical Device Maker
US Short Oil Poised for Double Top
US Optionable Healthcare Index
How-To Play Higher Oil Prices
Unloved Biotech Appears Ready for Advance
RXI's Top 13
Friday 13 Update
Play This Specialty Drug Maker with Options
May 24 Buy Recommendation Up 27%, Take Profits
$2 Cancer Play Advances on Q1 '10 Report
Options Strategy for Beaten Up Drug Maker
This BioPlastics Maker Is a Buy
Strong Buy Recommendation Reiterated
2 Sell Recommendations
Buy Gold
10 Buys Reiterated
16 Sell Recommendations
Underappreciated Specialty Drug Maker
Buffett Buys RXI Recommended Nalco
Good News from BioPlastics Maker
Positive News Before the Bell
5 Safe Bets in Tough Market
Pending Catalysts
Quick Notes: 7 Open Positions
Sell This Cancer Drug Maker
So, What's Next?
Sell Prices for RXI's Open Positions
Analysis of iShares NASDAQ Biotech ETF
Unknown, Promising Cancer Drug Maker Sub-$2
Sell This Drug Maker
$2 Buy Alert
POZN Obtains Approval, Hits New High
Time to Sell This Commodity
Recommended BioPlastics Maker Obtains EU Contract
Recommended BioPlastics Maker Advances 17.35%, Take Profits
State of the US Economy
Expect This BioPlastics Maker to Climb Substantially Higher (>100%) in 2010
Advancing Clean Energy Stocks
Two Drug Makers with Pending FDA Decisions
Dendreon Is Overvalued, But This Cancer Drug Maker Should Head Higher
A Play on Shock Absorption
Correction
A Basic Materials Buy
This Biotech Research Firm Is a Buy
Clean Energy Play with BIG Gain Potential
Fantastic 3
Take Profits in This Cancer Diagnostics Maker
Oil Spill Play
+Q2 2010 Results
ALERT: One Commodity You Must Own
Update: Fuel System Solutions
Notable Q2 2010 Results – Part II
Sell This Cancer Drug Maker
29 Notable Q2 2010 Reports
Q2 2010 Results
REGULAR CONTENT (New)
Spectrum Pharma: Temporary Setback
Ariad Pharma: Significant Catalysts Approaching
Spectrum Pharma: Zevalin and the Importance of Approval
Spectrum Pharma: Oversold and Undervalued
Epicept Advancing in Front of Priority Review
FDA Crushes Epicept
BioScrip Continues to Advance
Epicept Likely to Succeed with Regulatory Challenge
Independence Day 2010
Advances in Hand Surgery
My Call on KMGB
Cypress Biosciences (CYPB)
8 STRONG BUYS
Oxigene: Dirt Cheap, Lots of Potential
A Doc’s Take on Oxigene’s Zybrestat Ophthalmology Program
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
These Small Cap Cancer Drugmakers Have Big Growth Potential
Spectrum Pharma: Rumors of Buyout Talks Persist
Lucky 13 Portfolio: Fuel Systems & Three Cancer Drug Makers
Five Drug Makers with Pending Catalysts
SmartHeat: An Emerging Market Clean Energy Growth Play
Spectrum Pharma: Undervalued and (Now) Oversold
Spectrum Pharma: Zevalin Has Blockbuster Potential
Spectrum Pharma: Zevalin Sales Ramp Up
Spectrum Pharma: CMS Rules in Favor of Zevalin
Justin M. Hall's Call on Jazz Pharma (PDF)
Ground Zero Mosque
Orange County Business Journal
A Hidden Biotech Buy
Spectrum Pharma: Undervalued Growth Company with Strong Late-Stage Pipeline
Two Possible Approvals for Spectrum Pharmaceuticals
17 Reasons Why Bayer Might Acquire Spectrum Pharma
Justin M. Hall's Call on Cereplast
Immunogen's T-DM1 Delayed
Justin M. Hall's Call on Gold
Justin M. Hall's Call on Response Genetics
My Call on Innophos X2
Member Earns 200% Gain on Cypress Biosciences
Sell BioScrip
Spectrum Pharma: Optimistic About Zevalin's Prospects
Spectrum Pharma: Outlook Remains Very Promising
Ariad Pharma: Advancing in Front of Interim Phase 3 Results
Spectrum Pharma: Potential Acquisition Target
Spectrum Pharma: The Labor Day Catalyst
Spectrum Pharma: Despite Share Offering, Still Cheap vs. Other Cancer Drug Makers
How Zevalin Is Helping Spectrum
On Small Cap Drug Makers and Volatility
December's Game Plan for Biotech
Spectrum Pharma: Additional Trial Not Required
Three Underappreciated Cancer Drug Makers
BioScrip Sell-Off
OxiGene Jumps 30%+
Will You Buy GM at IPO?
Infinity Pharma: A Promising, Underappreciated Cancer Drug Maker
Spectrum Pharma: Looking Ahead at Continued Growth
Change Coming to US Healthcare
Member Feedback
BioPlastix & Clean Energy
Catalyst . Stocks
LEAPS
Position Disclosure
FOUNDER
Persist Until You Succeed
RESULTS
